Drug Information

Drug General Information
Drug ID
D0J0KT
Former ID
DCL000216
Drug Name
RhuDex
Indication Rheumatoid arthritis [ICD9: 710-719, 714; ICD10:M05-M06] Phase 2a [537129]
Company
MediGene AG
Target and Pathway
Target(s) T-lymphocyte activation antigen CD80 Target Info Inhibitor [551085]
KEGG Pathway Cell adhesion molecules (CAMs)
Toll-like receptor signaling pathway
Intestinal immune network for IgA production
Type I diabetes mellitus
Autoimmune thyroid disease
Systemic lupus erythematosus
Rheumatoid arthritis
Allograft rejection
Graft-versus-host disease
Viral myocarditis
NetPath Pathway Leptin Signaling Pathway
RANKL Signaling Pathway
PANTHER Pathway T cell activation
Pathway Interaction Database TCR signaling in na&#xef
TCR signaling in na&#xef
IL12 signaling mediated by STAT4
Reactome PIP3 activates AKT signaling
Constitutive Signaling by Aberrant PI3K in Cancer
CD28 co-stimulation
CD28 dependent PI3K/Akt signaling
CD28 dependent Vav1 pathway
CTLA4 inhibitory signaling
WikiPathways Toll-like receptor signaling pathway
Inflammatory Response Pathway
PIP3 activates AKT signaling
Primary Focal Segmental Glomerulosclerosis FSGS
Allograft Rejection
Costimulation by the CD28 family
Regulation of toll-like receptor signaling pathway
References
Ref 537129New developments in immunosuppressive therapy for heart transplantation. Expert Opin Emerg Drugs. 2009 Mar;14(1):1-21.
Ref 551085A phase 1 study of AS1409, a novel antibody-cytokine fusion protein, in patients with malignant melanoma or renal cell carcinoma. Clin Cancer Res. 2011 Apr 1;17(7):1998-2005.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.